glp 1 agonists vs sglt2 inhibitors GLP-1 Receptor and in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy | Drugs SGLT-2 Inhibitors and GLP-1 Agonists:
Description
(2025) Extended Data Fig

By combining semaglutide with cagrilintide (an amylin receptor agonist), this therapy has delivered weight loss results exceeding 20% in clinical trials
These are averages, meaning some individuals exceed them substantially

10.1200/JCO.23.02745 40 Gratacos-GinesJ.ArinoS.Sancho-BruP.BatallerR.PoseE

June 2019
